These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 8978598)
1. Lysosomal cathepsins B and L and Stefin A blood levels in patients with hepatocellular carcinoma and/or liver cirrhosis: potential clinical implications. Leto G; Tumminello FM; Pizzolanti G; Montalto G; Soresi M; Gebbia N Oncology; 1997; 54(1):79-83. PubMed ID: 8978598 [TBL] [Abstract][Full Text] [Related]
2. Cathepsin D, B and L circulating levels as prognostic markers of malignant progression. Tumminello FM; Leto G; Pizzolanti G; Candiloro V; Crescimanno M; Crosta L; Flandina C; Montalto G; Soresi M; Carroccio A; Bascone F; Ruggeri I; Ippolito S; Gebbia N Anticancer Res; 1996; 16(4B):2315-9. PubMed ID: 8694562 [TBL] [Abstract][Full Text] [Related]
3. Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients. Kos J; Stabuc B; Schweiger A; Krasovec M; Cimerman N; Kopitar-Jerala N; Vrhovec I Clin Cancer Res; 1997 Oct; 3(10):1815-22. PubMed ID: 9815568 [TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases, but not cathepsins B, H, and L or their inhibitors in peripheral blood of patients with rheumatoid arthritis are potentially useful markers of disease activity. Keyszer G; Lambiri I; Keysser M; Keysser C; Nagel R; Burmester GR; Jung K Z Rheumatol; 1998 Dec; 57(6):392-8. PubMed ID: 10025098 [TBL] [Abstract][Full Text] [Related]
5. Circadian characteristics of cathepsins B, H, L, and stefins A and B, potential markers for disease, in normal sera. Cimerman N; Brguljan PM; Krasovec M; Suskovic S; Kos J Clin Chim Acta; 1999 Apr; 282(1-2):211-8. PubMed ID: 10340450 [No Abstract] [Full Text] [Related]
6. Serum concentration and circadian profiles of cathepsins B, H and L, and their inhibitors, stefins A and B, in asthma. Cimerman N; Mesko Brguljan P; Krasovec M; Suskovic S; Kos J Clin Chim Acta; 2001 Aug; 310(2):113-22. PubMed ID: 11498076 [TBL] [Abstract][Full Text] [Related]
7. [Enzymatic activity of cathepsin B, cathepsin B and L, plasmin, trypsin and collagenase in hepatocellular carcinoma]. Niewczas M; Paczek L; Krawczyk M; Pawlak J; Bartłomiejczyk I; Górnicka B Pol Arch Med Wewn; 2002 Jul; 108(1):653-62. PubMed ID: 12412410 [TBL] [Abstract][Full Text] [Related]
8. Tissue Levels of Stefin A and Stefin B in Hepatocellular Carcinoma. Lin YY; Chen ZW; Lin ZP; Lin LB; Yang XM; Xu LY; Xie Q Anat Rec (Hoboken); 2016 Apr; 299(4):428-38. PubMed ID: 26753874 [TBL] [Abstract][Full Text] [Related]
9. Lysosomal aspartic and cysteine proteinases serum levels in patients with pancreatic cancer or pancreatitis. Leto G; Tumminello FM; Pizzolanti G; Montalto G; Soresi M; Carroccio A; Ippolito S; Gebbia N Pancreas; 1997 Jan; 14(1):22-7. PubMed ID: 8981503 [TBL] [Abstract][Full Text] [Related]
10. Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors. Lah TT; Nanni I; Trinkaus M; Metellus P; Dussert C; De Ridder L; Rajcević U; Blejec A; Martin PM J Neurosurg; 2010 May; 112(5):940-50. PubMed ID: 19747051 [TBL] [Abstract][Full Text] [Related]
11. Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients. Levicar N; Kos J; Blejec A; Golouh R; Vrhovec I; Frkovic-Grazio S; Lah TT Cancer Detect Prev; 2002; 26(1):42-9. PubMed ID: 12088202 [TBL] [Abstract][Full Text] [Related]
13. Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas. Trinkaus M; Vranic A; Dolenc VV; Lah TT Int J Biol Markers; 2005; 20(1):50-9. PubMed ID: 15832773 [TBL] [Abstract][Full Text] [Related]
14. Cathepsin D serum mass concentrations in patients with hepatocellular carcinoma and/or liver cirrhosis. Leto G; Tumminello FM; Pizzolanti G; Montalto G; Soresi M; Ruggeri I; Gebbia N Eur J Clin Chem Clin Biochem; 1996 Jul; 34(7):555-60. PubMed ID: 8864404 [TBL] [Abstract][Full Text] [Related]
15. Cathepsin expression in oral squamous cell carcinoma: relationship with clinicopathologic factors. Kawasaki G; Kato Y; Mizuno A Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2002 Apr; 93(4):446-54. PubMed ID: 12029284 [TBL] [Abstract][Full Text] [Related]
16. [Serum stefin A in patients with type 2 diabetes]. Piwowar A; Fus I; Kanapik-Kordecka M; Warwas M Pol Arch Med Wewn; 2004 Mar; 111(3):319-25. PubMed ID: 15230213 [TBL] [Abstract][Full Text] [Related]
17. Regulation of the activity of lysosomal cysteine proteinases by pH-induced inactivation and/or endogenous protein inhibitors, cystatins. Turk B; Bieth JG; Björk I; Dolenc I; Turk D; Cimerman N; Kos J; Colic A; Stoka V; Turk V Biol Chem Hoppe Seyler; 1995 Apr; 376(4):225-30. PubMed ID: 7626231 [TBL] [Abstract][Full Text] [Related]
18. The amino acid sequences, structure comparisons and inhibition kinetics of sheep cathepsin L and sheep stefin B. Ritonja A; Coetzer TH; Pike RN; Dennison C Comp Biochem Physiol B Biochem Mol Biol; 1996 Jun; 114(2):193-8. PubMed ID: 8759291 [TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical staining of cathepsins B, L and stefin A in human hypophysis and pituitary adenomas. Strojnik T; Lah TT; Zidanik B Anticancer Res; 2005; 25(1B):587-94. PubMed ID: 15816632 [TBL] [Abstract][Full Text] [Related]
20. Cathepsins B and L are markers for clinically invasive types of meningiomas. Strojnik T; Zidanik B; Kos J; Lah TT Neurosurgery; 2001 Mar; 48(3):598-605. PubMed ID: 11270551 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]